Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-fu infusion reduces colorectal liver metastases and improves survival in mice

International Journal of Cancer

Volumn 104, Issue 4, 2003, Pages 496-503

  Stoeltzing, Oliver ^a   Liu, Wenbiao ^a   Reinmuth, Niels ^a   Fan, Fan ^a   Parry, Graham C ^b   Parikh, Alexander A ^a   McCarty, Marya F ^a   Bucana, Corazon D ^a   Mazar, Andrew P ^b   Ellis, Lee M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Attenuon LLC   (United States)

Author keywords

Angiogenesis; Colon cancer; Integrins; Liver metastases

Indexed keywords

ALPHA5 INTEGRIN; ATN 161; BETA1 INTEGRIN; FLUOROURACIL; PEPTIDE; UNCLASSIFIED DRUG; ACETYL PROLYL HISTIDYL SERYL CYSTEINYL ASPARAGINAMIDE; ACETYL-PROLYL-HISTIDYL-SERYL-CYSTEINYL-ASPARAGINAMIDE; ANGIOGENESIS INHIBITOR; OLIGOPEPTIDE; VERY LATE ACTIVATION ANTIGEN 5;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CANCER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG POTENTIATION; ENDOTHELIUM CELL; FOLLOW UP; INOCULATION; LIVER METASTASIS; LIVER WEIGHT; MALE; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; PRIORITY JOURNAL; SURVIVAL RATE; ANIMAL; BAGG ALBINO MOUSE; CELL DIVISION; CELL SURVIVAL; COLORECTAL TUMOR; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; LIVER TUMOR; METASTASIS; PATHOLOGY; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; COLORECTAL NEOPLASMS; ENDOTHELIUM, VASCULAR; FLUOROURACIL; INTEGRIN ALPHA5BETA1; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; OLIGOPEPTIDES;

EID: 0037457423     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10958     Document Type: Article

References (42)

1. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-25.
2. Giancotti FG, Ruoslahti E. Integrin signaling. Science 1999;285:1028-32.
3. Varner JA, Emerson DA, Juliano RL. Integrin alpha 5 beta 1 expression negatively regulates cell growth: reversal by attachment to fibronectin. Mol Biol Cell 1995;6:725-40.
4. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Vamer JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:1500-2.
5. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994;79:1157-64.
6. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 1995;96:1815-22.
7. Kerr JS, Wexler RS, Mousa SA, Robinson CS, Wexler EJ, Mohamed S, Voss ME, Devenny JJ, Czerniak PM, Gudzelak A, Jr., Slee AM. Novel small molecule alpha v integrin antagonists: comparative anticancer efficacy with known angiogenesis inhibitors. Anticancer Res 1999;19:959-68.
8. Kerr JS, Slee AM, Mousa SA. Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opin Investig Drugs 2000;9:1271-9.
9. Kumar CC, Malkowski M, Yin Z, Tanghetti E, Yaremko B, Nechuta T, Varner J, Liu M, Smith EM, Neustadt B, Presta M, Armstrong L. Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res 2001;61:2232-8.
10. Kumar CC, Armstrong L, Yin Z, Malkowski M, Maxwell E, Ling H, Yaremko B, Liu M, Varner J, Smith EM, Neustadt B, Nechuta T. Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis. Adv Exp Med Biol 2000;476:169-80.
11. Klotz O, Park JK, Pleyer U, Hartmann C, Baatz H. Inhibition of corneal neovascularization by alpha(v)-integrin antagonists in the rat. Graefes Arch Clin Exp Ophthalmol 2000;238:88-93.
12. Storgard CM, Stupack DG, Jonczyk A, Goodman SL, Fox RI, Cheresh DA. Decreased angiogenesis and arthritic disease in rabbits treated with an alphavbeta3 antagonist. J Clin Invest 1999;103:47-54.
13. Kim S, Bell K, Mousa SA, Varner JA. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000;156:1345-62.
14. Gong J, Wang D, Sun L, Zborowska E, Willson JK, Brattain MG. Role of alpha 5 beta 1 integrin in determining malignant properties of colon carcinoma cells. Cell Growth Differ 1997;8:83-90.
15. Livant DL, Brabec RK, Pienta KJ, Allen DL, Kurachi K, Markwart S, Upadhyaya A. Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res 2000;60:309-20.
16. O'Brien V, Frisch SM, Juliano RL. Expression of the integrin alpha 5 subunit in HT29 colon carcinoma cells suppresses apoptosis triggered by serum deprivation. Exp Cell Res 1996;224:208-13.
17. Schreiner C, Bauer J, Margolis M, Juliano RL. Expression and role of integrins in adhesion of human colonic carcinoma cells to extracellular matrix components. Clin Exp Metastasis 1991;9:163-78.
18. White ES, Livant DL, Markwart S, Arenberg DA. Monocyte-fibronectin interactions, via alpha(5)beta(1) integrin, induce expression of CXC chemokine-dependent angiogenic activity. J Immunol 2001;167:5362-6.
19. Stoeltzing O, Liu W, Reinmuth N, Fan F, Livant DL, Mazar AP, Ellis LM. Reduction of colon cancer growth by a novel antiangiogenic agent that targets the integrin a5b1. Clin Cancer Res 2001;7:3656S.
20. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
21. Kase S, Kubota T, Watanabe M, Furukawa T, Tanino H, Ishibiki K, Teramoto T, Kitajima M. Interferon beta increases antitumor activity of 5-fluorouracil against human colon carcinoma cells in vitro and in vivo. Anticancer Res 1993;13:369-73.
22. Gately S, Kerbel R. Antiangiogenic scheduling of lower dose cancer chemotherapy. Cancer J 2001;7:427-36.
23. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
24. Kerbel RS, Viloria-Petit A, Klement G, Rak J. "Accidental" antiangiogenic drugs: anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. Eur J Cancer 2000;36:1248-57.
25. Kerbel RS, Klement G, Pritchard KI, Kamen B. Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-5.
26. Morikawa K, Morikawa R, Killion JJ, Fan D, Fidler IJ. Isolation of human colon carcinoma cells for resistance to a single interferon associated with cross-resistance to multiple recombinant interferons: alpha, beta, and gamma. J Natl Cancer Inst 1990;82:517-22.
27. Fidler IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therary of metastasis. Cancer Metastasis Rev 1991;10:229-43.
28. Remmenga SW, Colcher D, Gansow O, Pippen CG. Raubitschek A. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft. Gynecol Oncol 1994;55:115-22.
29. Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 1995;22:42-6.
30. Tedjarati S, Baker CH, Apte S, Huang S, Wolf JK, Killion JJ, Fidler IJ. Synergistic therapy of human ovarian carcinoma implanted orthotopically in nude mice by optimal biological dose of pegylated interferon alpha combined with Paclitaxel. Clin Cancer Res 2002;8:2413-22.
31. Baker CH, Solorzano CC, Fidler IJ. Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer. Cancer Res 2002;62:1996-2003.
32. Bruns CJ, Harbison MT, Davis DW, Portera CA, Tsan R, McCorkey DJ, Evans DB, Abbruzzese JL, Hicklin DJ, Radinsky R. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000;6:1936-48.
33. Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 2000;89:438-99.
34. Lode HN, Moehler T, Xiang R, Jonczyk A, Gillies SD, Cheresh DA, Reisfeld RA. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc Natl Acad Sci USA 1999;96:1591-6.
35. Griggs DW, Shannon KE, Keene JL, Settle SL, Duffin TD, Nickols MA, Schroeter S, Nickols GA, Westlin WF. Anti-metastatic efficacy mediated by peptidomimetic aVb3 integrin antagonists in orthotopic and experimental models. Proc Am Assoc Cancer Res 2001;42:1420.
36. Kim S, Harris M, Varner JA. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A. J Biol Chem 2000;275:33920-8.
37. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24.
38. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045-7.
39. Mross K. Anti-angiogenesis therapy: concepts and importance of dosing schedules in clinical trials. Drug Resist Updat 2000;3:223-35.
40. Klement G, Huang P, Mayer B, Green SK, Man S, Bohlen P, Hicklin D, Kerbel RS. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-32.
41. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM, et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001;61:7501-6.
42. Bergsland E, Hurwitz H, Fehrenbacher L, Meropol NJ, Novotny WF, Gaudreault J, Lieberman G, Kabbinavar F. A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) alone in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:242:A939.